DuPont today announced that it will invest an unspecified amount in tubing manufacturing improvements at its healthcare industries materials site in Hemlock, Mich.
Upgrades include extrusion capacity expansion for tubing, a new ISO 7 cleanroom, and ongoing elastomer capacity expansions with new mixing equipment for liquid silicone rubber (LSR) and high-consistency rubber (HCR), according to the Wilmington, Del.-based company.
DuPont said the investments will help it address challenges and opportunities in:
- Biopharma processing, to enable manufacturing of biologics used in drugs and vaccines with its pharma tubing and overmolded assemblies.
- Pharmaceutical solutions, to enable new drug-delivery routes with topical and transdermal products and gastrointestinal drug ingredients.
- Medical devices, to enable diagnostics, monitoring and treatment with specialty medical adhesives and elastomers for connected devices and wearables.
“Without question, these investments in the future of healthcare will help strengthen and grow the value of our DuPont Liveo brand healthcare silicone solutions,” said DuPont Liveo Healthcare global business director Eugenio Toccalino in a news release. “We believe that DuPont Healthcare will have a positive impact on every level of the healthcare industry value chain.”
DuPont Liveo is part of the company’s transportation & industrial business unit.
